An observational study in Mitral Regurgitation, sponsored by LMU Klinikum. Recruiting at 30 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-24.
Sponsored by LMU Klinikum · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Mitral Valve Insufficiency with a site in Germany — 24 open to participants now, 32 under way, none of them phase 3. Mitral Valve Insufficiency · Germany.
Among the 81 studies in Mitral Valve Insufficiency with a site in Germany, this one is the 14th largest by planned enrollment of the 33 observational ones that give a count, is one of 4 that started in 2021, is one of 33 observational ones, reaches primary completion later than 12 of the 31 other live ones, and was the 62nd registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →24 of the 81 studies in Mitral Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:
University Medical Center Mainz · Sites in Germany
Ages 18+
Jena University Hospital · Sites in Germany
Ages 18+
Medical University of Vienna · Sites in Germany, Austria, Italy and 1 more country
Ages 18+
4C Medical Technologies, Inc. · Sites in Germany, United States, Canada and 4 more countries
Ages 18+
LMU Klinikum · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 4 3
First in 2006; this study’s year is marked. 4 started in 2021.
This study's planned enrollment of 400 is above the median of 159 across 170 observational studies indexed under Mitral Valve Insufficiency.
Median enrollment 113 across the 48 interventional studies, 214 across the 33 observational. Of the 37 that completed or were terminated, 12 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 81 have an industry lead sponsor. The 10 most frequent:
LMU Klinikum is the lead sponsor of 53 studies on the registry; 20 are open to participants now.
LMU Klinikum has 3 studies filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Mitral Valve Insufficiency with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04029363HighLife SASExpanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk | 2026-12-15 |
| NCT03339115Cardiovalve Ltd.AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System | 2026-12-31 |
| NCT04898335LMU KlinikumTendyne European Experience Registry | 2026-12-31 |
| NCT06634121LMU KlinikumEfficacy of MitraCLip Vs. PASCAL for the TrEAtment of MitraL REgurgiTation in an All-comer Population | 2027-04-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 81 studies in Mitral Valve Insufficiency with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
TENDER is a multicenter, single-device, retrospective and prospective, observational study to assess safety and efficacy of the Tendyne Mitral Valve System in a real-world population.
Mitral regurgitation (MR) is a common disease and is associated with high morbidity and mortality if left untreated. Due to age and comorbidities, patients are often ineligible for surgical repair or replacement. Over the last years, transcatheter systems have been introduced as an alternative therapeutic approach. The Tendyne Mitral Valve System (Abbott Vascular, Roseville, Minnesota) is a transcatheter transapical, self-expanding valve prosthesis for mitral valve replacement. A recent study has proven safety and feasibilty of the system, leading to commercial approvement (CE mark). However, data on real world experience with the system are not available.
TENDER is a multicenter, single-device, retrospective and prospective, observational study. Objectives of the study are 1) to assess early outcomes, including safety and efficacy, in patients treated with the Tendyne Mitral Valve System for severe MR at 30 days, 2) to assess clinical outcomes in patients treated with the Tendyne Mitral Valve System for severe MR at 1 year and 3 year follow-up, and 3) to identify echocardiographic and CT-based anatomic predictors associated with outcomes.
All consecutive patients undergoing Implantation of Tendyne Mitral Valve System at the participating centres.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
all patients treated with a Tendyne Mitral Valve System
Device: Tendyne Mitral Valve System
Tendyne Mitral Valve System for mitral valve disease in a commercial setting
Rate of procedural success
Device success (structural and functional); absence of death, stroke, life-threatening bleeding, major vascular or cardiac structural complications, acute kidney injury, myocardial infarction, heart failure and valve-related dysfunction requiring repeat procedure
Time frame: 30 days
Rate of peri-procedural myocardial infarction
Myocardial infarction during the index procedure
Time frame: 1 day
Rate of conversion to open-heart surgery
Conversion to open-heart surgery during the index procedure
Time frame: 1 day
Rate of cardiac tamponade
Cardiac Tamponade during the index procedure
Time frame: 1 day
Rate of procedural mortality
Death during the index procedure
Time frame: 1 day
Rate of technical success (cumulative endpoint according to MVARC)
Absence of procedural mortality, successful access, delivery and retrieval of the delivery system, successful deployment and positioning, freedom from emergency surgery) Device success (according to MVARC): absence of procedural mortality or stroke, proper placement and positioning, freedom from unplaned procedure related to the device or access, continued safety and performance of the device (no structural or functional failure, no technical complications, reduction of MR ≤ 2+ and mitral valve gradient \< 5 mmHg)
Time frame: 1 day
Rate of device success (cumulative endpoint according to MVARC)
Absence of procedural mortality or stroke, proper placement and positioning, freedom from unplaned procedure related to the device or access, continued safety and performance of the device (no structural or functional failure, no technical complications, reduction of MR ≤ 2+ and mitral valve gradient \< 5 mmHg)
Time frame: 30 days, 1 year and 3 years
New York Heart Association (NYHA) functional class
class I - IV
Time frame: 30 days, 1 year and 3 years
6-minute walk distance (6MWD)
in m
Time frame: 30 days, 1 year and 3 years
BNP/NT-proBNP level
in pg/ml
Time frame: 30 days, 1 year and 3 years
Mitral regurgitation severity grade
grade 0/1+/2+/3+/4+
Time frame: 30 days, 1 year and 3 years
Left and right ventricular dimensions
left/right ventricular end-diastolic/-systolic diameter (in mm)
Time frame: 30 days, 1 year and 3 years
Left ventricular function
LVEF in percent
Time frame: 30 days, 1 year and 3 years
Right ventricular function
TAPSE in mm
Time frame: 30 days, 1 year and 3 years
Pulmonary artery pressure
in mmHg
Time frame: 30 days, 1 year and 3 years
Tricuspid regurgitation severity grade
grade 1-5
Time frame: 30 days, 1 year and 3 years
Transprosthetic gradient
in mmHg
Time frame: 30 days, 1 year and 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2021 (actual). Primary completion is estimated for Dec 2026, 68 months after the start.
Of 73 non-industry observational studies under Mitral Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 192. This study's planned 68 months is above that.
Counting every sponsor, half of 85 studies reached it within 57 months; a quarter within 26 and three quarters within 192.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
LMU Klinikum